Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Philogen

Boehringer Ingelheim headquarters

Boehringer adds to pipeline again with €628m Autifony CNS deal

Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia

- PMLiVE

Boehringer claims EU okay for Humira biosimilar

But won’t launch before expiration of the respective SPC for adalimumab in October 2018

- PMLiVE

Boehringer builds evidence base for its Humira biosimilar

Cyltezo shows clinical equivalence to AbbVie's blockbuster in a late-stage trial

- PMLiVE

Novartis gets EU nod for leukaemia drug Rydapt

The FLT3 inhibitor adds to its US approval in AML

- PMLiVE

Boehringer Ingelheim launches new digital innovation team

BI X will aim to accelerate research and development

- PMLiVE

New EU and US approvals for Humira biosimilars

Samsung’s Imraldi and Boehringer Ingelheim’s Cyltezo receives nod from EMA and FDA, respectively

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s leukaemia drug Besponsa

Firm plans to appeal the final appraisal determination on its orphan drug

- PMLiVE

FDA clears Pfizer’s leukaemia drug Besponsa

The breakthrough treatment is the first CD22-targeted ADC to be approved in the US

- PMLiVE

NICE rejects Pfizer’s antibody drug for leukaemia

Trial shows no survival benefit from Besponsa compared to current treatment

- PMLiVE

Boehringer Ingelheim calls for “strong and united” Europe

Simone Menne highlights the EU's achievements, and her firm's contribution

- PMLiVE

Juno gives up on lead CAR-T drug after deaths

ROCKET trial for leukaemia patients ended

Celgene building

Celgene bags US priority review for cancer metabolism drug

First approval for enasidenib could be just six months away

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links